GLP-1 therapy cost is one of the first practical questions people ask when they start researching weight loss medications, and for good reason. The price difference between different pathways is significant enough to determine whether treatment is accessible at all. A GLP-1 cost comparison in 2026 needs to account for brand-name pricing, compounded medication pricing, the insurance landscape, and what you actually get for what you pay across different platforms.

This article lays out the landscape honestly and clearly so you can go into any platform consultation with the right questions.

The brand-name GLP-1 medications that most people have heard of, Ozempic, Wegovy, Mounjaro, and Zepbound, carry retail prices that are among the highest for any medication class in the United States.

Without insurance, Wegovy (semaglutide 2.4mg, FDA-approved for obesity) runs approximately $1,300 to $1,400 per month at retail pharmacy prices. Ozempic (semaglutide in lower doses, FDA-approved for type 2 diabetes) is slightly less but still in the $900 to $1,100 per month range without coverage. Zepbound (tirzepatide, FDA-approved for obesity) is similarly priced to Wegovy.

These prices reflect the substantial R&D investment behind these medications and the monopoly pricing structure of branded pharmaceuticals in the US market. For most people without insurance coverage, brand-name GLP-1 therapy at these prices is simply not accessible as a sustained treatment.

Insurance coverage for GLP-1 medications is uneven and often frustrating to navigate.

Ozempic and Mounjaro are generally covered for patients with a type 2 diabetes diagnosis who meet certain clinical criteria. Coverage for the obesity-indicated formulations, Wegovy and Zepbound, is more variable. Medicare historically did not cover weight loss medications, though this has been changing. Medicaid coverage varies by state. Commercial insurance coverage for obesity-indicated GLP-1s ranges from generous to nonexistent depending on the plan.

Even when coverage exists in principle, prior authorization requirements, formulary restrictions, step therapy requirements, and high copays can make access practically difficult. Many patients who technically have coverage spend weeks navigating the process before receiving medication.

Some manufacturers offer savings programs or copay cards for commercially insured patients, which can reduce out-of-pocket costs significantly. These programs have specific eligibility requirements and do not apply to patients with government insurance.

The net result is that a substantial portion of patients who would benefit from GLP-1 therapy do not access it through brand-name channels because of cost.

This is where the telehealth GLP-1 market enters the picture. Compounded semaglutide, produced by licensed compounding pharmacies rather than brand-name manufacturers, typically costs a fraction of brand-name pricing.

In 2026, compounded GLP-1 programs through telehealth platforms generally range from roughly $150 to $400 per month depending on the platform, the dose level, and what is included in the subscription. This is a significant difference from brand-name pricing, though exact pricing changes as the market evolves and regulatory conditions shift.

At EllieMD, pricing for the weight loss program is structured to be competitive within the telehealth GLP-1 market. Your consultation includes transparent pricing information, and your physician will make sure you understand exactly what you are paying for before you commit. We would encourage verifying current pricing directly with any platform you are comparing, as numbers in this market shift with regulatory changes and supply conditions.

A GLP-1 cost comparison that only looks at medication price misses something important: what you are getting alongside the medication differs meaningfully between platforms.

At the low end of the market, some services function as pure prescription delivery: a brief online consultation, a prescription, medication by mail, and not much else. This works for some patients and not for others.

EllieMD's program includes physician oversight throughout treatment, not just at the initial consultation. It includes access to the EllieMD community, which the Northwestern University research cited on our platform suggests significantly improves outcomes. It includes a formulation that adds L-carnitine to support fat oxidation alongside the appetite effects of GLP-1 therapy. And it includes the option of a structured microdosing approach for patients who want it.

The point is not that more features always means better value. The point is that comparing monthly costs without understanding what is included at each price point can lead to a decision based on incomplete information.

The cost landscape for compounded GLP-1 medications is connected to the FDA shortage designation system. When semaglutide was on the FDA shortage list, compounding pharmacies could legally produce copies of the medication under certain conditions. Changes to shortage status affect the legal pathway for compounding and, consequently, the availability and pricing of compounded options.

This regulatory situation has been dynamic in 2025 and 2026, and any platform operating in this space should be transparent with patients about how regulatory changes might affect their access to medication. At EllieMD, your physician keeps you informed of any changes that affect your program options. Our article on compounded semaglutide safety covers the regulatory context in more detail.

Price is a legitimate and important consideration. But deciding based only on monthly cost leaves out questions that matter at least as much for whether you actually achieve your weight loss goals.

How much physician access do you get if you have side effects or questions mid-cycle? What is the community and accountability structure? What happens if your dose needs adjustment? What does the pharmacy quality look like behind the medication?

The best GLP-1 value is the program you actually stay on long enough to get results. A slightly lower monthly cost does not represent savings if it comes without the support structure that keeps you adherent. See our comparison article on the best GLP-1 programs in 2026 for a fuller look at how platforms compare on the dimensions beyond price.


Individual results may vary. All prescriptions require approval by a licensed medical provider. Compounded medications are not FDA-approved. EllieMD facilitates access to independent healthcare providers and pharmacies and does not provide medical care or dispense medications.